Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dermal Safety Study of XF-73

Trial Profile

Phase 1 Dermal Safety Study of XF-73

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Exeporfinium chloride (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jan 2019 Results published in a Destiny pharma media release.
    • 13 Apr 2018 New trial record
    • 12 Apr 2018 According to a Destiny Pharma media release, first subject has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top